Rinvoq for UC Cost: Oral JAK Inhibitor Price, Copay Card, and Medicare

A once-daily pill for ulcerative colitis that skips the infusion chair entirely — that’s the appeal of Rinvoq. The catch shows up at the pharmacy: a list price around $6,000 a month, roughly $70,000 to $72,000 a year. Before that number scares you off, know that the pill’s convenience comes with copay help that drops most patients to almost nothing.

Rinvoq is the brand name for upadacitinib, a JAK inhibitor the FDA approved for ulcerative colitis in 2022 and Crohn’s disease in 2023. Unlike the big biologics, it’s an oral tablet — no IV, no self-injection — which changes both the experience and how it’s billed.

Rinvoq Cost Snapshot

Because Rinvoq is oral, it runs entirely through your pharmacy benefit — no separate facility fee, no medical-benefit split like an infusion. That makes the billing simpler than Entyvio or Remicade, though the specialty-tier copay can still be steep without assistance.

The JAK Inhibitor Tradeoff

JAK inhibitors carry a boxed warning about serious infections, blood clots, and cardiovascular events, so insurers and the FDA generally position them after a biologic has failed. That step-therapy placement affects both your approval odds and, indirectly, your cost timeline.

What Insured Patients Pay

AbbVie’s Rinvoq Complete program offers copay assistance for commercially insured patients, typically bringing your monthly out-of-pocket to $0-$5. Because it’s a pharmacy-benefit drug, the copay card applies cleanly — just watch for accumulator programs that stop those dollars from counting toward your deductible.

Medicare patients can’t use the card, but the Inflation Reduction Act’s $2,000 annual Part D cap, effective January 2025, limits total out-of-pocket exposure dramatically compared to the old coinsurance structure. Before that cap, a Part D patient on Rinvoq could easily have faced several thousand dollars a year in coinsurance once they hit the catastrophic phase — so this is one of the most meaningful changes in recent drug-pricing policy for UC patients.

There’s also a 90-day supply angle. Because Rinvoq is a maintenance drug you’ll likely take indefinitely, ask whether your plan offers a 90-day fill through mail order. It won’t change the per-month list price, but it can reduce pharmacy trips and sometimes lowers your effective copay per month.

Rinvoq Among UC Treatment Options

Rinvoq is one of several advanced therapies for ulcerative colitis. For the full lineup and how the prices compare, see our ulcerative colitis medication cost guide. Most patients start on cheaper drugs first — the mesalamine medication cost breakdown covers the entry-level therapy insurers require before approving anything advanced.

Rinvoq is also approved for Crohn’s, where it competes with the injected biologics. See our Crohn’s disease biologic medication cost guide for that comparison.

Prior Authorization and Step Therapy

Rinvoq almost always requires prior authorization plus step therapy. Insurers typically want a confirmed UC diagnosis with colonoscopy documentation and proof that conventional therapy and at least one biologic failed or weren’t tolerated. The boxed warning means some plans add extra screening requirements, like TB testing and cardiovascular risk assessment.

The diagnostics that establish your UC diagnosis aren’t cheap either. If you’re trying to budget the whole picture, our colonoscopy cost guide breaks down the procedure side that often precedes a Rinvoq prescription.

The Bottom Line

Rinvoq’s roughly $6,000-a-month list price is real, but its oral form keeps the billing clean and its copay card keeps most insured patients at $0 to $5. On Medicare, the new $2,000 cap protects you. The main hurdle isn’t price — it’s step therapy, since the JAK boxed warning means you’ll likely need to fail a biologic first. Get your prior authorization sorted and your specialty pharmacy to confirm out-of-pocket before you start.